![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 7, 2024
Big data projects near activation; APP Working Group builds momentum; ECOG-ACRIN welcomes Winn CILA scholar
March 7, 2024
ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
March 7, 2024
This cancer care delivery study aims to provide out-of-pocket cost estimates and remote counseling to assist patients in navigating the financial aspects of cancer treatment
March 7, 2024
Dr. Marshall's research focuses on the genetics of prostate cancer, as well as clonal hematopoiesis, a risk factor for cardiovascular disease that may be relevant to prostate cancer
March 7, 2024
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more